课题基金 / 基金详情

Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls

Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls
开发特异性 Mu 阿片受体拮抗剂以逆转芬太尼的急性和慢性毒性
批准号:
10476705
负责人:
YAN ZHANG
金额:
$282.44万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-07-01 至 2024-06-30

项目摘要

项目成果

YAN ZHANG的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary This proposal is in response to PAR-20-092: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional). We propose to develop novel MOR antagonists carrying 1-phenethyl-N-phenylpiperidin-4-amine skeleton to effectively and specifically reverse the acute toxicity of fentanyl and its analogs. The fentanyls are a large family of synthetic opioids and are prominent on the list of opioid abuse and addiction due to the fact that some of them are up to 10,000-fold more potent than morphine. Because of their high potency and longer half-life than naloxone, the front-line treatment for fentanyl overdose, multiple infusions and high doses of naloxone may be required during reversal procedure. Another fentanyl addiction treatment, naltrexone, has been reported with patient non-compliance and unwanted side effects. Recently we have identified a novel molecular mechanism of fentanyl binding and activation on its target protein, the MOR, through systematic computational chemistry and biochemistry studies. More importantly, we identified a new fentanyl derivative, phenylfentanil, as a potent antagonist of the MOR. Phenylfentanil shares the same structural skeleton, i.e. 1-phenethyl-N-phenylpiperidin-4-amine, with fentanyl. It carries reasonably high affinity to the MOR and acts as a neutral antagonist on the receptor based on recent studies. Accordingly, we plan to apply these findings to further characterize phenylfentanil and its derivatives with similar pharmacological characteristics both in vitro and in vivo, and pursue preclinical development on these leads as novel reversal agents against the acute toxicity of fentanyl. In the UG3 phase, we plan to pursue two specific aims in order to define novel leads with reasonable potency and pharmacokinetics profiles as fentanyl reversal agents while in the UH3 phase, we propose to conduct IND-enabling studies on the most promising candidate and eventually file an IND with the FDA by the end of the funding period.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhance the security and resilience of the national food safety system
  • 批准号:
    10783485
  • 项目类别:
  • 资助金额:
    $3.07万
  • 财政年份:
    2023
  • 负责人:
    YAN ZHANG
  • 依托单位:
Microbiology - Whole Genome Sequencing Analytical Track
Microbiology - Whole Genome Sequencing Analytical Track
Whole genome sequencing for outbreak investigations of foodborne pathogens and antimicrobial resistance studies for FDA Vet-LIRN
海外基金